Free Newsletter
LRPR1: A new target for obesity, diabetes
Researchers at the University of Cincinnati have identified a new target for drug developers out to control obesity and diabetes. David Hui, PhD, and colleagues say that they knocked out adipocyte low density lipoprotein receptor-related protein 1, or LRPR1, cell receptors in mice and registered a dramatic physical response. The knockout mice stored less fat and gained less weight while expending more energy than control mice. A separate group of researchers at UT Southwestern Medical Center undertook the same experiment and duplicated the results, confirming the promise of this approach.
"Our study has shown this molecule directly impacts the rate of fat transport in the body, so with further study it could be a new target for drugs aimed at controlling obesity," says Hui.
"This shows that LRPR1 is a critical regulator of lipid absorption in fat cells," said Susana Hoffman, a pathology research professor at UC and a member of Hui's team. "Preventing these interactions in our model prevented the onset of obesity and diabetes."
- check out the release on the study
- here's the UPI report
Related Articles:
Common virus is a culprit in obesity. Report
Molecular research points to new obesity therapy. Report
Scripps researchers find anti-obesity vaccine. Report
Enzyme discovery offers new direction in diabetes. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment